Matthew C. Kapusta Sells 6,717 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 6,717 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This represents a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

uniQure Trading Up 3.4 %

Shares of NASDAQ QURE opened at $12.07 on Friday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock’s 50 day moving average price is $15.12 and its two-hundred day moving average price is $9.75. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The stock has a market capitalization of $588.33 million, a P/E ratio of -2.43 and a beta of 0.38.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its stake in uniQure by 49.1% during the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 89,400 shares during the last quarter. Ballentine Partners LLC acquired a new position in shares of uniQure in the 3rd quarter valued at about $116,000. abrdn plc grew its position in shares of uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. Finally, Atria Investments Inc acquired a new stake in uniQure during the third quarter worth about $53,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

QURE has been the subject of several analyst reports. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Stifel Nicolaus lifted their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, February 5th. Finally, HC Wainwright lifted their price objective on uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.